BRIEF-Takeda Pharmaceutical Co Ltd - Takeda Announces U.S. FDA Accepts NDA And Grants Priority Review For Rusfertide As A Potential First-In-Class Therapy For Polycythemia Vera

March 2 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T:

  • TAKEDA PHARMACEUTICAL CO LTD: TAKEDA ANNOUNCES U.S. FDA ACCEPTS NDA AND GRANTS PRIORITY REVIEW FOR RUSFERTIDE AS A POTENTIAL FIRST-IN-CLASS THERAPY FOR POLYCYTHEMIA VERA

  • TAKEDA PHARMACEUTICAL CO LTD: IMPACT ON TAKEDA'S FINANCIAL RESULTS FOR FISCAL YEAR ENDING MARCH 31, 2026 (FY2025), FOLLOWING ACCEPTANCE OF NDA, IS IMMATERIAL

Source text: ID:nTSob8bf58

Further company coverage: 4502.T


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.